Author/Authors :
Yavari ، Samira Department of Cellular and Molecular Biology - Faculty of Advanced Science and Technology - Islamic Azad University, Tehran Medical Sciences Branch , Naseroleslami ، Maryam Department of Cellular and Molecular Biology - Faculty of Advanced Science and Technology - Islamic Azad University, Tehran Medical Sciences Branch , Peymani ، Maryam Department of Biology - Faculty of Basic Sciences - Islamic Azad University, Shahrekord Branch , Yekani ، Farshid Department of Animal Biology - Faculty of Biological Sciences - Kharazmi University , Khayam Nekouei ، Niloufar Department of Cellular and Molecular Biology - Faculty of Advanced Science and Technology - Islamic Azad University, Tehran Medical Sciences Branch
Abstract :
Objective: The objective of this study was to assess whether Spen paralogue and orthologue C-terminal domaincontaining 1 (SPOCD1) gene expression could serve as a valuable prognostic and diagnostic biomarker in commoncancers, drawing from insights in recent literature. We sought to verify this concept by utilizing data sourced from TheCancer Genome Atlas (TCGA) alongside clinical samples. Materials and Methods: In this bioinformatics and experimental study, SPOCD1 RNA-seq data from 12 commoncancers were collected from TCGA Pan-Cancer Atlas using the R package TCGA BIOLINKS and normalized foranalysis. Various analytical tools, including receiver operating characteristic (ROC) curves, Kaplan-Meier and Coxregressionanalyses, and pathway enrichment analysis via the molecular signatures database (MSigDB), were applied.Drug resistance/sensitivity correlations with SPOCD1 expression were explored using the Gene Expression Omnibus(GEO) database. Clinical colorectal cancer (CRC) samples, including both colon and rectal malignant samples, werealso evaluated. Results: The results showed elevated SPOCD1 expression in most cancers (9/12), with notable prognostic valuein COAD, HNSC, KICH, and LIHC, and a correlation with poor prognosis in COAD for disease-free survival. ROCcurve analysis suggested SPOCD1 as a diagnostic biomarker in the majority of cases (7/12), although this patternwas inconsistent in clinical CRC samples. Pathway enrichment analysis revealed a strong correlation betweenSPOCD1 expression and critical molecular pathways. Unlike former results, we found that SPOCD1 upregulatedwhen interacting with PD-0325901. However, treating with Panobinostat led to downregulation. Both are as anticancerreagents. Conclusion: This study confirms the potential of SPOCD1 as a diagnostic and prognostic biomarker in prevalentcancers. However, extensive clinical data, particularly for CRC, are required to validate its reliability. DifferentCOAD subtypes may exhibit varying correlations with SPOCD1 expression levels, underscoring the need for furtherinvestigation to fully understand its diagnostic and prognostic value.
Keywords :
Bioinformatics , Diagnostic , Prognostic , SPOCD1 Expression , The Cancer Genome Atlas
